When it comes to finding growth in the UK, we are positive on the pharmaceuticals sector.
Slight recovery in investor confidence
Out of over 7,000 firms
Male CEOs earn up to 110% more than females
Bias towards income payers
'Style of the fund has changed dramatically'
Third anniversary this month
Bought into banks for first time since 2003
2016 saw several blow-ups for large drug companies
As the Evenlode Income fund celebrates its seventh anniversary, fund manager Hugh Yarrow highlights the best performing stocks from its portfolio.
Best ideas from host countries since 1980
Focus on high-quality companies
The Merchants trust's Simon Gergel explains why investing in one of the UK's biggest healthcare stocks - GlaxoSmithKline - is not as simple as many investors envisage
Appeal of non-traditional financials
Still positive on prospects
Concerns over sector M&A
Simon Gergel, manager of the Merchants trust, explains why he is shunning recently re-rated mid caps in favour of "disappointing" mega caps.
Blue chips jump 1.6%
Scott McKenzie, investment director and manager of the Saracen UK Income fund, says the largest dividend payers in the UK market currently offer limited potential for growth, particularly as the strong dollar is masking inherent weaknesses in many business...
Mark Barnett has told Investment Week he is "concerned" over the fortunes of GlaxoSmithKline, a core holding in the Invesco Perpetual Income funds which he began running at the start of March 2014.
Threadneedle's Richard Colwell is adding more to stocks including Centrica and GlaxoSmithKline as he seeks contrarian equity income plays for the months ahead.
As people live longer than ever before and traditional sources of income fail to yield enough for lengthy retirement periods, choosing the correct income source is becoming essential.
Managing the low inflation challenge